CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies

Parnetti, L., Lanari, A., Amici, S., Gallai, V., Vanmechelen, E., Hulstaert, F.·2001·Neurological Sciences
DOI 10.1007/s100720170055

Cited by (127)

Items 101–127 of 127

  1. Bridging Molecular Genetics and Biomarkers in Lewy Body and Related Disorders
    G. Ho, W. Liang, M. Waragai, K. Sekiyama, E. Masliah, M. Hashimoto · 2011 · International Journal of Alzheimer's Disease
  2. Genomic and Proteomic Biomarker Discovery in Neurological Disease
    Rilee H Robeson, Andrew M Siegel, T. Dunckley · 2008 · Biomarker Insights
  3. Biological markers of Alzheimer's disease
    Pankaj D Mehta, Tuula Pirttilä · 2002 · Drug Development Research
  4. Investigating the Potential Impact of Air Pollution on Alzheimer’s Disease and the Utility of Multidimensional Imaging for Early Detection
    Ankul Singh S, Mohd Nazam Ansari, Gehan M. Elossaily, Chitra Vellapandian, Bhupendra Gopalbhai Prajapati · 2024 · ACS Omega
  5. Structural Magnetic Resonance Imaging Markers of Alzheimer’s Disease and Its Retranslation to Rodent Models
    Zsigmond Tamás Kincses, András Király, Dániel Veréb, László Vécsei · 2015 · Journal of Alzheimer s Disease
  6. Application of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) in Alzheimer’s disease
    Agatha Grela, Agata Turek, W. Piekoszewski · 2012 · Clinical Chemistry and Laboratory Medicine
  7. Hyperphosphorylated tau protein in the cerebrospinal fluid of patients with Alzheimer's disease and other dementias: preliminary findings.
    A. P. J. Hartmann, S. D. de Almeida, J. Livramento, R. Nitrini, D. Takahashi, P. Caramelli · 2004 · Arquivos de Neuro-Psiquiatria
  8. Neurochemical dementia diagnostics for Alzheimer's disease and other dementias: an ISO 15189 perspective.
    J. Waedt, Martina Kleinow, J. Kornhuber, P. Lewczuk · 2012 · Biomarkers in Medicine
  9. The Erlangen Score Algorithm in the diagnosis and prediction of the progression from subjective cognitive decline and mild cognitive impairment to Alzheimer-type dementia
    Anna Filipek-Gliszczyńska, Anna K. Barczak, Magdalena Budziszewska, Monika Mandecka, Tomasz Gabryelewicz, Maria Barcikowska · 2018 · Folia Neuropathologica
  10. Cross-Sectional and Longitudinal Hippocampal Atrophy, Not Cortical Thinning, Occurs in Amyloid-Negative, p-Tau-Positive, Older Adults With Non-Amyloid Pathology and Mild Cognitive Impairment
    Swati Rane Levendovszky · 2022 · Frontiers in Neuroimaging
  11. Currently Available Biomarkers and Strategies for the Validation of Novel Candidates for Neurochemical Dementia Diagnostics in Alzheimer’s Disease and Mild Cognitive Impairment
    P. Lewczuk · 2014 · Advances in Geriatrics
  12. Candidate Bio-Markers of Alzheimer’s Disease
    Balachandran Krishnamma Binukumar, Chandrashekaran Harish · 2013 · InTech eBooks
  13. The Search for Biomarkers in Alzheimer's Disease
    Anna Meiliana, Andi Wijaya · 2010 · The Indonesian Biomedical Journal
  14. Vers un diagnostic biologique de la maladie d’Alzheimer et des syndromes apparentés
    Pierre Krolak‐Salmon, Jérémie Seguin, Armand Perret‐Liaudet, Virginie Desestret, Alain Vighetto, Marc Bonnefoy · 2008 · La Revue de Médecine Interne
  15. Current perspectives in dementia with Lewy bodies
    A. Rongve, D. Aarsland, C. Ballard · 2006
  16. Investigating the Association Between Verbal Forgetting and Pathological Markers of Alzheimer’s and Lewy Body Diseases
    Morgan J. Schaeffer, Alzheimer’s Disease Neuroimaging Initiative, Brandy L. Callahan · 2019 · Journal of Alzheimer s Disease
  17. Alzheimer’s Diseases: Towards Biomarkers for an Early Diagnosis
    Benaïssa Elmoualij, Ingrid Dupiereux-Fettweis, Jérémie Seguin, Isabelle Quadrio, Willy Zorzi, Armand Perret‐Liaudet, Ernst Heine · 2011 · InTech eBooks
  18. Bedeutung der Gesamt-τ- und Phospho-τ-Protein-Liquorspiegel in der Demenzdiagnostik
    J. Hort, Martin Vališ, G. Waberžinek, R. Taláb, L. Glossová, M. Bojar, M. Vyhnálek, D. Škoda, J. Masopust, P. Šťourač · 2008 · Der Nervenarzt
  19. Biomarkers in Blood and Cerebrospinal Fluid
    H. Hampel, K. Buerger · 2006
  20. Alpha-synuclein in cerebrospinal fluid
    T. Tokuda, R. Ishii, H. Tatebe, T. Kasai, O. el-Agnaf · 2017 · Springer eBooks
  21. Role of Nanotechnology in the Diagnosis and Treatment of Alzheimer’s Disease
    Kristen M. Jaruszewski, Rajesh S. Omtri, Karunya K. Kandimalla · 2012 · BENTHAM SCIENCE PUBLISHERS eBooks
  22. Analysis of Effect of Non-drug intervention on the Elderly with Dementia in Korea: Meta-Analysis
    Na-Rae Lee, Y. Park, Jong-sik Jang · 2021 · Journal of the Korea Academia-Industrial cooperation Society
  23. Imaging of Neurotransmitter Systems in Dementia
    S. Hasselbalch, G. Knudsen · 2016 · CRC Press eBooks
  24. CSF proteome profiling reveals highly specific biomarkers for dementia with Lewy bodies.
    M. del Campo, L. Vermunt, C. Peeters, Y. Hok-A-Hin, A. Lleó, D. Alcolea, M. V. van Nee, S. Engelborghs, A. Sieben, A. Chen-Plotkin et al. · 2023 · medRxiv
  25. Disease specific cerebrospinal fluid investigations
    F. Deisenhammer, R. Egg, G. Giovannoni, B. Hemmer, A. Petzold, F. Sellebjerg, C. Teunissen, H. Tumani · 2011
  26. PMD2 A META-ANALYSIS OF BIOMARKERS AND DIAGNOSTIC IMAGING IN ALZHEIMER'S DISEASE
    Sean D. Sullivan, Lisa M. Bloudek, David Eldon Spackman, Michael Blankenburg · 2011 · Value in Health
  27. Clinical Evaluation and Treatment of Cognitive Dysfunction and Dementia
    L. A. van de Pol, W. M. van der Flier, P. Scheltens · 2009 · Humana Press eBooks